Bausch+Lomb Results Presentation Deck

1Q22 Financial Highlights & Segment Drivers - Revenue Millions USD Revenue 881 1Q21 889 1Q22 +5% organic revenue ¹,2 growth driven by focus on commercial execution and BAUSCH + LOMB investment, leading to strong demand across key franchises Strong performance notwithstanding FX headwind of $29M and -$10M revenue impact from COVID-19 China lockdown . Vision Care 62% $560M 38% Contact Lens ■Consumer 1 Q 22 +4% Continued market leadership position in Ocuvite® + PreserVision (+7% reported revenue growth) and Lumify® (+35% reported revenue growth) ORGANIC Increasing market share5 in Daily SiHy (+41% reported revenue growth) • BioTrue® Solutions Franchise (+19% reported revenue growth); BioTrue® Eye Hydration brand expansion Surgical 26% 54% $174M . ■ Implantables ■ Equipment ■ Consumables/Other 20% REVENUE +13% • Market recovery / backlog of elective surgeries Growth in implantables (+5% reported revenue growth), driven by en Vista® Entry into premium IOL category with LuxSmartTM IOL in international markets 1. This is a non-GAAP measure or ratio. See Slide 2 and Appendix for further information on non-GAAP measures and ratios. 2. Organic growth/change, a non-GAAP ratio, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations. IQVIA NPA monthly.. 3 4 B+L Consumer Data Science, IRI, Total US Omnichannel, Panel, Unit Sales, L52WE 3-20-2022. 5. GfK U.S. Daily SiHy Shares by Manufacturer. Unit Shares, Rolling 13 Months (March 2022) . . . . Ophthalmic Pharmaceuticals 43% $155M U.S. International CHANGE 57% 1,2 -3% Strong organic growth ¹.2 in international markets (+10% reported revenue growth and +16% organic revenue growth ¹.2) Vyzulta® saw 44% TRX growth³ U.S. impacted by tail end of LOE products and generic performance and competition Transformation underway: launch of XipereⓇ in 1Q22 and anticipated NOV03 in 2023 7

View entire presentation